Detection Bias

Detection bias refers to systematic differences between study groups in how outcomes are identified, measured, or assessed. In clinical trials, detection bias occurs most commonly when outcome assessors are aware of participants' treatment assignments, which may consciously or unconsciously influence their evaluation of outcomes. Related terms include observer bias and ascertainment bias. Blinding (masking) of outcome assessors is the primary method for reducing detection bias.

Detection bias can inflate or deflate the apparent effect of a treatment, leading to conclusions that do not reflect the true treatment effect. If assessors who know a patient is receiving an experimental drug are more likely to interpret ambiguous symptoms as improvement, the treatment will appear more effective than it actually is. Conversely, if assessors are skeptical of the treatment, they may be more stringent in their evaluation of treated patients. The original Cochrane Risk of Bias tool assessed blinding of outcome assessment as a domain of its own, and its successor, RoB 2, covers it in the domain on bias in measurement of the outcome; systematic reviews routinely assess detection bias as part of their risk of bias appraisal. In regulatory submissions, evidence of adequate assessor blinding strengthens the credibility of efficacy claims.

Detection bias arises through several mechanisms. When outcome assessment involves subjective judgment, as in grading tumor response, rating symptom severity, diagnosing a condition, or evaluating physical function, the assessor's expectations can influence their interpretation. Knowledge that a patient received the experimental treatment creates an expectation of improvement that can shift borderline assessments toward favorable outcomes. This effect is not limited to consciously biased assessors; research on expectation effects demonstrates that even well intentioned assessors are susceptible to unconscious influence.

The primary strategy for reducing detection bias is blinding outcome assessors to treatment allocation. In double blind trials, neither participants nor assessors know who received which treatment. In open label trials where participant and clinician blinding is impossible (such as surgical trials or behavioral interventions), blinded outcome assessment can still be achieved by using independent assessors who have no contact with the clinical team and no access to treatment assignment information.

Objective outcomes are less susceptible to detection bias than subjective outcomes. A mortality endpoint is generally resistant to assessor bias because death is an objective and verifiable event. However, even seemingly objective outcomes can be influenced: the decision to order a diagnostic test that might detect an event, the timing of assessments, and the criteria applied for classification all involve judgment that can be affected by knowledge of treatment assignment.

Differential follow up, where one group is monitored more intensively than the other, is another mechanism for detection bias. If treated patients are seen more frequently or receive more diagnostic testing, outcomes may be detected at higher rates in the treated group regardless of any true treatment effect.

Awareness of detection bias is important in the design, conduct, and appraisal of any study that involves outcome assessment. Steps to prevent detection bias should be built into the study protocol, including blinding procedures, standardized assessment protocols, and training for outcome assessors. When appraising existing studies, reviewers should assess the adequacy of assessor blinding as part of risk of bias evaluation. The Cochrane Risk of Bias 2 tool and the Newcastle Ottawa Scale for observational studies both include items for evaluating detection bias.

A common error is assuming that blinding participants eliminates detection bias. Participant blinding addresses performance bias (differences in behavior due to treatment knowledge), and it protects outcomes that participants report themselves, because for those outcomes the participant is the outcome assessor. It does not address detection bias in outcomes assessed by other people unless those assessors are also blinded. Another mistake is claiming that outcomes are "objective" and therefore not susceptible to detection bias without examining whether the classification process involves judgment. Researchers sometimes fail to verify that blinding was maintained throughout the study; assessors who become unblinded due to side effects, laboratory values, or inadvertent disclosure remain susceptible to bias. In systematic reviews, failing to distinguish between detection bias and performance bias when assessing risk of bias produces imprecise quality appraisals. Finally, open label studies that do not implement blinded outcome assessment when it is feasible miss an opportunity to reduce a significant source of bias.

A randomized trial comparing arthroscopic surgery to physical therapy for meniscal tears uses blinded outcome assessment to reduce detection bias. An independent physiotherapist who does not know which treatment each patient received measures knee function with standardized physical performance tests at 6 and 12 months. To maintain blinding, patients are instructed not to mention their treatment during the assessment visit, they wear clothing that covers the knee so that surgical scars are not visible, and assessments are conducted in a separate clinic from the treating surgeons. A post study survey finds that the assessor correctly guessed treatment assignment in 52% of cases, close to the 50% expected by chance, which supports the adequacy of the blinding procedure. The trial's patient reported outcome, the KOOS questionnaire, cannot be protected in the same way: patients know which treatment they received and complete the questionnaire themselves, so that outcome remains at higher risk of detection bias.